Section: Bilateral Contracts and Grants with Industry

Contracts and Grants with Industry

Implication in research for the development of Ebola vaccine has lead to several indirect contracts with industry:

• The EBOVAC1, EBOVAC2 and EBOVAC3 project, collaboration with Janssen from Johnson et Johnson.

• The Prevac trial vaccine trial (legal sponsors: Inserm, NIH, London School of Hygiene and Tropical Medicine) involves collaborations with Merck and Janssen. The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults. Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA) boost, or the rVSV$\Delta$G-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo. The EDCTP-2 funded Prevac-UP project is set as a continuation of Prevac trial in the same framework.

A new collaboration has started with the pharma company Ipsen on the integration of OMICS data into an in-silico trials pipeline (Cifre Phd to start in January 2020)